The role of tropomyosin in heart disease

Advances in Experimental Medicine and Biology

Volumn 644, Issue , 2008, Pages 132-142

  Wieczorek, David F ^a   Jagatheesan, Ganapathy ^a   Rajan, Sudarsan ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MYOSIN; TROPOMYOSIN;

ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEART; HEART DISEASE; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CARDIOVASCULAR DISEASES; HEART; HEART DISEASES; HUMANS; MICE; MODELS, BIOLOGICAL; MYOSINS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RATS; SIGNAL TRANSDUCTION; TROPOMYOSIN;

EID: 60849112865     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-85766-4_11     Document Type: Article

References (53)

1. Klein L, O'Connor CM, Gattis WA et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am J Cardiol 2003; 91(9A):18F-40F. (Pubitemid 36555737)
2. Rothermel BA, Berenji K, Tannous P et al. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. Physiol Genomics 2005; 23(1):18-27.
3. Cummins P, Perry SV. Chemical and immunochemical characteristics of tropomyosins from striated and smooth muscle. Biochem J 1974; 141(1):43-49.
4. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 1988; 85(2):339-343.
5. Wang SM, Greaser ML, Schultz E et al. Studies on cardiac myofibrillogenesis with antibodies to titin, actin, tropomyosin and myosin. J Cell Biol 1988; 107(3):1075-1083.
6. Muthuchamy M, Pajak L, Howles P et al. Developmental analysis of tropomyosin gene expression in embryonic stem cells and mouse embryos. Mol Cell Biol 1993; 13(6):3311-3323. (Pubitemid 23157269)
7. Muthuchamy M, Grupp IL, Grupp G et al. Molecular and physiological effects of overexpressing striated muscle beta-tropomyosin in the adult murine heart. J Biol Chem 1995; 270(51):30593-30603.
8. Muthuchamy M, Pieples K, Rethinasamy P et al. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. Circ Res 1999; 85(1):47-56. (Pubitemid 29321041)
9. Prabhakar R, Boivin GP, Grupp IL et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001; 33(10):1815-1828. (Pubitemid 32977135)
10. Jagatheesan G, Rajan S, Petrashevskaya N et al. Functional importance of the carboxyl-terminal region of striated muscle tropomyosin. J Biol Chem 2003; 278(25):23204-23211. (Pubitemid 36830387)
11. Jagatheesan G, Rajan S, Petrashevskaya N et al. Physiological significance of troponin T binding domains in striated muscle tropomyosin. Am J Physiol Heart Circ Physiol 2004; 287(4):H1484-1494. (Pubitemid 39313250)
12. Rajan S, Ahmed RP, Jagatheesan G et al. Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity. Circ Res 2007; 101(2):205-214. (Pubitemid 47196588)
13. 2+, strong cross-bridge binding and protein phosphorylation. J Biol Chem 1996; 271(20):11611-11614.
14. 2+ and altered dynamics of contraction and relaxation in transgenic cardiac cells that express beta-tropomyosin. Circ Res 1999; 84(7):745-751. (Pubitemid 29181481)
15. Pieples K, Wieczorek DF. Tropomyosin 3 increases striated muscle isoform diversity. Biochemistry 2000; 39(28):8291-8297. (Pubitemid 30460981)
16. Pieples K, Arteaga G, Solaro RJ et al. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol 2002; 283(4): H1344-1353.
17. Geisterfer-Lowrance AA, Kass S, Tanigawa G et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990; 62(5):999-1006.
18. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287(10):1308-1320. (Pubitemid 34250486)
19. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104(4):557-567. (Pubitemid 32201950)
20. Watkins H, MacRae C, Thierfelder L et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993; 3(4):333-337. (Pubitemid 23112959)
21. Thierfelder L, Watkins H, MacRae C et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994; 77(5):701-712.
22. Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005; 10(3):237-248. (Pubitemid 43115833)
23. Nakajima-Taniguchi C, Matsui H, Nagata S et al. Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 1995; 27(9):2053-2058.
24. Yamauchi-Takihara K, Nakajima-Taniguchi C, Matsui H et al. Clinical implications of hypertrophic cardiomyopathy associated with mutations in the alpha-tropomyosin gene. Heart 1996; 76(1):63-65. (Pubitemid 26267141)
25. Jaaskelainen P, Soranta M, Miettinen R et al. The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol 1998; 32(6):1709-1716. (Pubitemid 28545212)
26. Coviello DA, Maron BJ, Spirito P et al. Clinical features of hypertrophic cardiomyopathy caused by mutation of a "hot spot" in the alpha-tropomyosin gene. J Am Coll Cardiol 1997; 29(3):635-640. (Pubitemid 27116108)
27. Jongbloed RJ, Marcelis CL, Doevendans PA et al. Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41(6):981-986. (Pubitemid 36315541)
28. Karibe A, Tobacman LS, Strand J et al. Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling and poor prognosis. Circulation 2001; 103(1):65-71. (Pubitemid 32050437)
29. Olson TM, Kishimoto NY, Whitby FG et al. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001; 33(4):723-732. (Pubitemid 32538985)
30. Kremneva E, Boussouf S, Nikolaeva O et al. Effects of two familial hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on the thermal unfolding of actin-bound tropomyosin. Biophys J 2004; 87(6):3922-3933. (Pubitemid 39602898)
31. Hernandez OM, Housmans PR, Potter JD. Invited Review: pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation. J Appl Physiol 2001; 90(3):1125-1136. (Pubitemid 32171404)
32. Michele DE, Albayya FP, Metzger JM. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes. Nat Med 1999; 5(12):1413-1417.
33. Prabhakar R, Petrashevskaya N, Schwartz A et al. A mouse model of familial hypertrophic cardiomyopathy caused by a alpha-tropomyosin mutation. Mol Cell Biochem 2003; 251(1-2):33-42. (Pubitemid 37220706)
34. Westfall MV, Borton AR, Albayya FP et al. Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res 2002; 91(6):525-531.
35. Bottinelli R, Coviello DA, Redwood CS et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998; 82(1):106-115. (Pubitemid 28074023)
36. Michele DE, Gomez CA, Hong KE et al. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent and improved by beta-blockade. Circ Res 2002; 91(3):255-262. (Pubitemid 34875681)
37. Evans CC, Pena JR, Phillips RM et al. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2000; 279(5): H2414-2423.
38. 2+ regulation of thin filament motility. Biochem Biophys Res Commun 1997; 236(3):760-764. (Pubitemid 27384705)
39. Golitsina N, An Y, Greenfield NJ et al. Effects of two familial hypertrophic cardiomyopathy-causing mutations on alpha-tropomyosin structure and function. Biochemistry 1997; 36(15):4637-4642. (Pubitemid 27180313)
40. Bing W, Knott A, Redwood C et al. Effect of hypertrophic cardiomyopathy mutations in human cardiac muscle alpha -tropomyosin (Asp175Asn and Glu180Gly) on the regulatory properties of human cardiac troponin determined by in vitro motility assay. J Mol Cell Cardiol 2000; 32(8):1489-1498.
41. Schachat FH, Bronson DD, McDonald OB. Heterogeneity of contractile proteins. A continuum of troponin-tropomyosin expression in mammalian skeletal muscle. J Biol Chem 1985; 260(2):1108-1113. (Pubitemid 15125610)
42. Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev 2005; 10(3):225-235. (Pubitemid 43115832)
43. Regitz-Zagrosek V, Erdmann J, Wellnhofer E et al. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation 2000; 102(17): E112-116.
44. Brown JH, Kim KH, Jun G et al. Deciphering the design of the tropomyosin molecule. Proc Natl Acad Sci USA 2001; 98(15):8496-8501. (Pubitemid 32678056)
45. Mirza M, Marston S, Willott R et al. Dilated cardiomyopathy mutations in three thin filament regulatory proteins result in a common functional phenotype. J Biol Chem 2005; 280(31):28498-28506. (Pubitemid 41105750)
46. Mirza M, Robinson P, Kremneva E et al. The effect of mutations in alpha-tropomyosin (E40K and E54K) that cause familial dilated cardiomyopathy on the regulatory mechanism of cardiac muscle thin filaments. J Biol Chem 2007; 282(18):13487-13497. (Pubitemid 47100552)
47. Jagatheesan G, Rajan S, Petrashevskaya N et al. Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis. Am J Physiol Heart Circ Physiol 2007; 293(2):H949-958. (Pubitemid 47254193)
48. Pena J, Urboniene D, Goldspink P et al. Phospholamban knockout prevents the development of hypertrophy and cardiac dysfunction in a FHC alpha-tropomyosin (Glu180Gly) mouse model. Paper presented at: Keystone Symposia: Molecular Biology of Cardiac Diseases and Regeneration 2005; Steamboat Springs, CO.
49. Pena JR, Goldspink PH, Prabhakar R et al. Neonatal Gene Transfer of SERCA2a Improves the Response to ß-Adrenergic Stimulation in the -Tropomyosin (Glu180Gly) MouseModel of Familial Hypertrophic Cardiomyopathy. Paper presented at: Scientific Conference on Molecular Mechanisms of Growth, Death and Regeneration in the Myocardium: Basic Biology and Insights Into Ischemic Heart Disease and Heart Failure 2003; Snowbird Conference Center, Snowbird, Utah.
50. Coutu P, Bennett CN, Favre EG et al. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 2004; 94(9):1235-1241. (Pubitemid 38656410)
51. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988; 63(5):911-922. (Pubitemid 18269289)
52. Du CK, Morimoto S, Nishii K et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007; 101(2):185-194. (Pubitemid 47196586)
53. Rajan S, Williams SS, Jagatheesan G et al. Microarray analysis of gene expression during early stages of mild and severe cardiac hypertrophy. Physiol Genomics 2006; 27(3):309-317. (Pubitemid 46708782)